Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deutenzalutamide Plus ADT in High-Risk Biochemical Recurrence of Prostate Cancer
NCT07875881Phase 3Not yet recruiting
- Sponsor
- Hinova Pharmaceuticals Inc.
- Start
- Oct 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Deutenzalutamide Soft Capsules+ ADT with Placebo+ ADT (2 arms). Primary endpoint: Metastasis-Free Survival. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
deutenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07875881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07875881.